Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
Molecular Pharmacology|June 9, 2006
Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administrationLaura J Sim-Selley, Nicole S Schechter, W Kirk Rorrer, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2024
Effects of Repeated Treatment with the Monoacylglycerol Lipase Inhibitor MJN110 on Pain-Related Depression of Nesting and Cannabinoid 1 Receptor Function in Male and Female MiceClare M Diester, Hallie Balint, James C Gillespie, et al.
RSC Chemical Biology|May 26, 2025
Exploring substitution effects on the potential dominant conformations of NBF derivatives leading to functional conversion at the mu opioid receptorEnnian Li, Ahmed Reda, Hongguang Ma, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2007
Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinolDiana L McKinney, Michael P Cassidy, Lauren M Collier, et al.
British Journal of Pharmacology|June 19, 2007
Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine toleranceL J Sim-Selley, K L Scoggins, M P Cassidy, et al.
Bioorganic Chemistry|January 30, 2022
Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimersHongguang Ma, Mengchu Li, Piyusha P Pagare, et al.
Psychopharmacology|June 13, 2020
Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathyJulie A Meade, Y Alkhlaif, K M Contreras, et al.
Medchemcomm|May 18, 2013
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional ActivitiesYunyun Yuan, Christopher K Arnatt, Nazira El-Hage, et al.
Journal of Medicinal Chemistry|March 8, 2022
Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation TreatmentBoshi Huang, Mengchu Li, Pornprom Klongkumnuankarn, et al.
Journal of Medicinal Chemistry|July 6, 2026
Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological ProfilingNeha Upadhyay, Logan T Neel, Ennian Li, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
Molecular Pharmacology|June 9, 2006
Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administrationLaura J Sim-Selley, Nicole S Schechter, W Kirk Rorrer, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2024
Effects of Repeated Treatment with the Monoacylglycerol Lipase Inhibitor MJN110 on Pain-Related Depression of Nesting and Cannabinoid 1 Receptor Function in Male and Female MiceClare M Diester, Hallie Balint, James C Gillespie, et al.
RSC Chemical Biology|May 26, 2025
Exploring substitution effects on the potential dominant conformations of NBF derivatives leading to functional conversion at the mu opioid receptorEnnian Li, Ahmed Reda, Hongguang Ma, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2007
Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinolDiana L McKinney, Michael P Cassidy, Lauren M Collier, et al.
British Journal of Pharmacology|June 19, 2007
Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine toleranceL J Sim-Selley, K L Scoggins, M P Cassidy, et al.
Bioorganic Chemistry|January 30, 2022
Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimersHongguang Ma, Mengchu Li, Piyusha P Pagare, et al.
Psychopharmacology|June 13, 2020
Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathyJulie A Meade, Y Alkhlaif, K M Contreras, et al.
Medchemcomm|May 18, 2013
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional ActivitiesYunyun Yuan, Christopher K Arnatt, Nazira El-Hage, et al.
Journal of Medicinal Chemistry|March 8, 2022
Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation TreatmentBoshi Huang, Mengchu Li, Pornprom Klongkumnuankarn, et al.
Journal of Medicinal Chemistry|July 6, 2026
Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological ProfilingNeha Upadhyay, Logan T Neel, Ennian Li, et al.
Pageof 15